Launch of the Radioligand Therapy Readiness Assessment Framework

25 May 2021

Join The Health Policy Partnership for a webinar and an in-depth discussion on health system readiness for radioligand therapy, with representatives from the International Atomic Energy Agency, Society of Nuclear Medicine and Molecular Imaging, European Association of Urology, and American Society for Radiation Oncology, among others.

The webinar will be an ancillary event to the American Society of Clinical Oncology 2021 Conference. It will mark the launch of the Radioligand Therapy Readiness Assessment Framework – a new tool to assess the current integration of radioligand therapy into national health systems and evaluate future readiness for the approach.

The event will help us to increase awareness of radioligand therapy in cancer care and the need to assess system readiness, highlighting the role that the new framework can play in this process. The speakers will outline what a readiness policy environment for radioligand therapy looks like, followed by a deep-dive analysis of clinical readiness in the US.

The webinar will take place on Wednesday 9 June at 10:00–11:45 CDT. It will be moderated by Dr Suzanne Wait (The Health Policy Partnership).


  • Professor Ken Herrmann, University of Essen
  • Dr Diana Paez, International Atomic Energy Agency
  • Josh Mailman, NorCal CarciNET
  • Professor Hein Van Poppel, European Association of Urology
  • Dr Ajay Gopal, Seattle Cancer Care Alliance
  • Dr Michael Morris, Memorial Sloan Kettering Cancer Center
  • Dr Richard Wahl, Society of Nuclear Medicine and Molecular Imaging
  • Dr Ronald Ennis, American Society for Radiation Oncology
  • Dr Jolanta Kunikowska, European Association of Nuclear Medicine

Click here to register for the webinar.